A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Seagen Inc.
Seagen Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
BioNTech SE
Genentech, Inc.
Boehringer Ingelheim
University of Cincinnati
Fox Chase Cancer Center
Providence Health & Services
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Institutes of Health Clinical Center (CC)
Alpha Tau Medical LTD.
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
Bicara Therapeutics
Mayo Clinic
University of California, Davis
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neonc Technologies, Inc.
Universität des Saarlandes
Tizona Therapeutics, Inc
Institut Claudius Regaud
Emory University
Ohio State University Comprehensive Cancer Center
VLP Therapeutics
Brown University
VM Oncology, LLC
Memorial Sloan Kettering Cancer Center
Rakuten Medical, Inc.
ImmVira Pharma Co. Ltd
Scancell Ltd
Taipei Veterans General Hospital, Taiwan
Epkin
Bicara Therapeutics
Medicenna Therapeutics, Inc.
Dana-Farber Cancer Institute
Iovance Biotherapeutics, Inc.
Rapa Therapeutics LLC
Precision Biologics, Inc
TiumBio Co., Ltd.
University of Pittsburgh
Merus B.V.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Presage Biosciences
CJ Bioscience, Inc.
Nykode Therapeutics ASA